<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033471</url>
  </required_header>
  <id_info>
    <org_study_id>464</org_study_id>
    <nct_id>NCT04033471</nct_id>
  </id_info>
  <brief_title>Combined Epidural Morphine and Midazolam on Postoperative Pain</brief_title>
  <official_title>Effect of Epidural Morphine and Midazolam on Postoperative Painin Patients Undergoing Major Abdominal Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study aim to Compare the effect of preoperative Epidural Midazolam, Morphine and their&#xD;
      combination in postoperative pain relief and total morphine consumption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major abdominal surgeries with abdominal incisions lead to severe abdominal pain, which if&#xD;
      treated inadequately, can cause shallow breathing, atelectasis, retention of secretions and&#xD;
      lack of cooperation in physiotherapy. This increases the incidence of post-operative&#xD;
      morbidity and leads to delayed recovery.Epidural anesthesia is safe and inexpensive technique&#xD;
      with the advantage of providing surgical anesthesia and prolonged postoperative pain relief.&#xD;
      It also an effective treatment of operative pain blunts autonomic, somatic and endocrine&#xD;
      responses. Morphine and midazolam can be used as adjuvant to bupivicain to reduced the&#xD;
      postoperative pain&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>epidural bupiviacain</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first request of analgesia</measure>
    <time_frame>1st 48 hours postoperative</time_frame>
    <description>the time between the end of operation and tracheal extubation to the first request for supplemental analgesics and its administration to the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the cumulative consumption of morphine in the 1st 48h postoperatively</measure>
    <time_frame>1st 48 hours postoperative</time_frame>
    <description>total amount of morphine used for analgesia</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>MI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% + midazolam 5mg in total volume 10m1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine 0.25% + midazolam 5mg and morphine 5mg in total volume 10ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bupivacaine 0.25% + morphine 5 mg in total volume 10 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given</description>
    <arm_group_label>MI</arm_group_label>
    <arm_group_label>MM</arm_group_label>
    <arm_group_label>MO</arm_group_label>
    <other_name>morphine</other_name>
    <other_name>bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I-II patients scheduled for major abdominal cancer surgeries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with known allergy to the study drugs,&#xD;
&#xD;
          -  significant cardiac, respiratory, renal or hepatic disease,&#xD;
&#xD;
          -  drug or alcohol abuse,&#xD;
&#xD;
          -  psychiatric illness that would interfere with perception and assessment of pain.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shereen M Kamal, Associate proferssor</last_name>
    <phone>01006279209</phone>
    <email>sheridouh79@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khaled M Fares, proferssor</last_name>
    <phone>01289757288</phone>
    <email>faressali@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shereen M Kamal, Degree</last_name>
      <phone>01006279209</phone>
      <email>sheridouh79@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Khaled M Fares, Professor</last_name>
      <phone>01289757288</phone>
      <email>faressali@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shereen Mamdouh</investigator_full_name>
    <investigator_title>associate professor of anesthesia, ICU and pain manegement</investigator_title>
  </responsible_party>
  <keyword>epidural, morphine, midazolam, acute postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

